Consistent with angiotensin receptor blockers, growth factors such as FGF23 can significantly reduce the levels of inflammation and oxidative stress and further decrease renal fibrosis and lipid metabolic disorders during the progress of diabetic nephropathy, mainly by blocking the RAAS, enhancing the expression of Klotho, and inhibiting the expression of MCP-1/TNF-α and TGF-β [81, 82]. The gene discussed is TGFB1; the disease is renal fibrosis.